Diagnosis and treatment of bladder cancer

Sanjeev Sharma, Pankaj Ksheersagar, Poonam K Sharma

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Bladder cancer is the sixth most prevalent malignancy in the United States. The most common type of bladder cancer is urothelial (transitional cell) carcinoma, and cystoscopy remains the mainstay of diagnosis and surveillance. Fluorescence cystoscopy offers improvement in the detection of flat neoplastic lesions, such as carcinoma in situ. Non-muscle-invasive bladder cancer is typically managed with transurethral resection and perioperative intravesical chemotherapy. Intravesical bacille Calmette-Guérin therapy is preferred over mitomycin for those at high risk of disease progression. For muscle-invasive disease, standard management is radical cystectomy. In these patients, neoadjuvant chemotherapy or postoperative adjuvant chemotherapy should be considered based on pathologic risks, such as positive lymph nodes or pathologic T stage. Multidrug systemic chemotherapy involving cisplatin is commonly used. No major organization recommends screening for bladder cancer.

Original languageEnglish
Pages (from-to)717-723
Number of pages7
JournalAmerican Family Physician
Volume80
Issue number7
StatePublished - Oct 1 2009

Fingerprint

Urinary Bladder Neoplasms
Cystoscopy
Drug Therapy
Transitional Cell Carcinoma
Cystectomy
Carcinoma in Situ
Mitomycin
Therapeutics
Adjuvant Chemotherapy
Cisplatin
Disease Progression
Fluorescence
Lymph Nodes
Muscles
Neoplasms

All Science Journal Classification (ASJC) codes

  • Family Practice

Cite this

Sharma, S., Ksheersagar, P., & Sharma, P. K. (2009). Diagnosis and treatment of bladder cancer. American Family Physician, 80(7), 717-723.

Diagnosis and treatment of bladder cancer. / Sharma, Sanjeev; Ksheersagar, Pankaj; Sharma, Poonam K.

In: American Family Physician, Vol. 80, No. 7, 01.10.2009, p. 717-723.

Research output: Contribution to journalReview article

Sharma, S, Ksheersagar, P & Sharma, PK 2009, 'Diagnosis and treatment of bladder cancer', American Family Physician, vol. 80, no. 7, pp. 717-723.
Sharma S, Ksheersagar P, Sharma PK. Diagnosis and treatment of bladder cancer. American Family Physician. 2009 Oct 1;80(7):717-723.
Sharma, Sanjeev ; Ksheersagar, Pankaj ; Sharma, Poonam K. / Diagnosis and treatment of bladder cancer. In: American Family Physician. 2009 ; Vol. 80, No. 7. pp. 717-723.
@article{9667d60bd905446a82651b0cb2e01f75,
title = "Diagnosis and treatment of bladder cancer",
abstract = "Bladder cancer is the sixth most prevalent malignancy in the United States. The most common type of bladder cancer is urothelial (transitional cell) carcinoma, and cystoscopy remains the mainstay of diagnosis and surveillance. Fluorescence cystoscopy offers improvement in the detection of flat neoplastic lesions, such as carcinoma in situ. Non-muscle-invasive bladder cancer is typically managed with transurethral resection and perioperative intravesical chemotherapy. Intravesical bacille Calmette-Gu{\'e}rin therapy is preferred over mitomycin for those at high risk of disease progression. For muscle-invasive disease, standard management is radical cystectomy. In these patients, neoadjuvant chemotherapy or postoperative adjuvant chemotherapy should be considered based on pathologic risks, such as positive lymph nodes or pathologic T stage. Multidrug systemic chemotherapy involving cisplatin is commonly used. No major organization recommends screening for bladder cancer.",
author = "Sanjeev Sharma and Pankaj Ksheersagar and Sharma, {Poonam K}",
year = "2009",
month = "10",
day = "1",
language = "English",
volume = "80",
pages = "717--723",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "7",

}

TY - JOUR

T1 - Diagnosis and treatment of bladder cancer

AU - Sharma, Sanjeev

AU - Ksheersagar, Pankaj

AU - Sharma, Poonam K

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Bladder cancer is the sixth most prevalent malignancy in the United States. The most common type of bladder cancer is urothelial (transitional cell) carcinoma, and cystoscopy remains the mainstay of diagnosis and surveillance. Fluorescence cystoscopy offers improvement in the detection of flat neoplastic lesions, such as carcinoma in situ. Non-muscle-invasive bladder cancer is typically managed with transurethral resection and perioperative intravesical chemotherapy. Intravesical bacille Calmette-Guérin therapy is preferred over mitomycin for those at high risk of disease progression. For muscle-invasive disease, standard management is radical cystectomy. In these patients, neoadjuvant chemotherapy or postoperative adjuvant chemotherapy should be considered based on pathologic risks, such as positive lymph nodes or pathologic T stage. Multidrug systemic chemotherapy involving cisplatin is commonly used. No major organization recommends screening for bladder cancer.

AB - Bladder cancer is the sixth most prevalent malignancy in the United States. The most common type of bladder cancer is urothelial (transitional cell) carcinoma, and cystoscopy remains the mainstay of diagnosis and surveillance. Fluorescence cystoscopy offers improvement in the detection of flat neoplastic lesions, such as carcinoma in situ. Non-muscle-invasive bladder cancer is typically managed with transurethral resection and perioperative intravesical chemotherapy. Intravesical bacille Calmette-Guérin therapy is preferred over mitomycin for those at high risk of disease progression. For muscle-invasive disease, standard management is radical cystectomy. In these patients, neoadjuvant chemotherapy or postoperative adjuvant chemotherapy should be considered based on pathologic risks, such as positive lymph nodes or pathologic T stage. Multidrug systemic chemotherapy involving cisplatin is commonly used. No major organization recommends screening for bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=70349643764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349643764&partnerID=8YFLogxK

M3 - Review article

VL - 80

SP - 717

EP - 723

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 7

ER -